Drug Profile
Research programme: AMPA receptor agonists - RespireRx
Alternative Names: Ampakines; CX 929; CX1501; CX1763; CX1796; CX1837; CX1846; CX1942; CX2007; CX2076; CX516; CX614; CX707Latest Information Update: 10 Aug 2020
Price :
$50
*
At a glance
- Originator Cortex Pharmaceuticals
- Developer Cortex Pharmaceuticals; RespireRx Pharmaceuticals
- Class Antidementias; Antidepressants; Antiparkinsonians; Antipsychotics; Anxiolytics; Sleep disorder therapies; Small molecules
- Mechanism of Action AMPA receptor agonists; Brain derived neurotrophic factor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Anxiety disorders; Attention-deficit hyperactivity disorder; Fragile X syndrome; Huntington's disease; Major depressive disorder; Mild cognitive impairment; Parkinson's disease; Rett syndrome; Schizophrenia; Sleep apnoea syndrome; Spinal cord injuries; Stroke
- Discontinued Autistic disorder; Chronic brain damage; Respiratory insufficiency